Literature DB >> 16429656

[Comparison of the response to I-PSS according to the mode of administration of the questionnaire: by the doctor or self-assessment by the patient].

Alain Ruffion1, Nathalie Marionneau, Charles Taïeb, Paul Perrin.   

Abstract

OBJECTIVE: To compare the response to I-PSS according to its mode of administration (by the doctor versus self-assessment).
METHODS: 388 patients were included during the 3 months following a diagnosis of benign prostatic hyperplasia. The general practitioner completed the I-PSS and gave an I-PSS questionnaire to the patient to be completed at home and returned in a reply-paid envelope to the data entry centre. The Bland & Altman method was used to visualize individual differences and to quantify the bias between the two modes of evaluation.
RESULTS: The doctor overestimated the I-PSS by an average of 1.3 points [95% CI: 0.9-1.7]. In 42% of patients, these individual differences were 3 points or more. Significant overestimation was confirmed at 6, 12 and 18 months of follow-up.
CONCLUSION: A significant bias was demonstrated according to the mode of administration of the I-PSS. We therefore recommend that the same mode of administration should be maintained during clinical trials.

Entities:  

Mesh:

Year:  2005        PMID: 16429656

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride.

Authors:  Kirill V Kosilov; Irina G Kuzina; Vladimir Kuznetsov; Ekaterina K Kosilova
Journal:  Prostate Int       Date:  2020-02-25

2.  Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Olga Barabash; Ekaterina Fedorishcheva
Journal:  Asian J Urol       Date:  2021-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.